🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9918939

Formulation of Syk inhibitors

GILEAD CONNECTICUT, INC. · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9918983

Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells

THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS · Granted Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9913843

Protein kinase C inhibitors and uses thereof

Rigel Pharmaceuticals, Inc. · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914723

Small molecule inhibitors of Mcl-1 and uses thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9908878

Inhibitors of influenza viruses replication

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9908899

Histone deacetylase inhibitors

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9896445

Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

Ansana BioSciences, LLC · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890126

Synthesis of novel inhibitors of isoprenoid biosynthesis (ISPF)

Beryllium Discovery Corp. · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9890163

Inhibitors of protein kinases

Princeton Drug Discovery, Inc · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9889081

Aldehyde dehydrogenase inhibitors as novel depigmenting agents

The Board of Regents of the University of Texas System · Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9885042

miR-92 inhibitors and uses thereof

MIRAGEN THERAPEUTICS, INC. · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884841

Small molecule inhibitors of Mcl-1 and uses thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884868

TGF-beta inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9884807

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878993

DNA-PK inhibitors for treatment of cancer

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878996

2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric ox

Northwestern University · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9878992

GDF-8 inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873685

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873718

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeu

The Regents of the University of California · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9873696

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9868736

Deubiquitinase inhibitors and methods for use of the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9862679

Potent and selective inhibitors of monoamine transporters; method of making; and use there

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9855252

Methods of treating keratin hyperproliferation disorders using mTOR inhibitors

PALVELLA THERAPEUTICS, INC. · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9855305

Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and

Compass Therapeutics LLC · Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted